Подписаться
Danylo Halytsky Lviv National Medical University
Danylo Halytsky Lviv National Medical University
Подтвержден адрес электронной почты в домене meduniv.lviv.ua - Главная страница
Название
Процитировано
Процитировано
Год
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
New England Journal of Medicine 371 (23), 2167-2177, 2014
35412014
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The Lancet 393 (10183), 1819-1830, 2019
28332019
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
20992015
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label …
L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet 394 (10212), 1929-1939, 2019
15122019
Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines
C Schauer, C Janko, LE Munoz, Y Zhao, D Kienhöfer, B Frey, M Lell, ...
Nature medicine 20 (5), 511-517, 2014
9122014
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
MER O'Brien, TE Ciuleanu, H Tsekov, Y Shparyk, B Cuceviá, G Juhasz, ...
Journal of Clinical Oncology 24 (34), 5441-5447, 2006
7212006
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials
A Lipton, K Fizazi, AT Stopeck, DH Henry, JE Brown, DA Yardley, ...
European journal of cancer 48 (16), 3082-3092, 2012
6332012
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, ...
The Lancet 388 (10063), 2997-3005, 2016
6042016
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal …
JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 34 (5), 443-451, 2016
5782016
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ...
The Lancet Neurology 8 (10), 889-897, 2009
5152009
Host DNases prevent vascular occlusion by neutrophil extracellular traps
M Jiménez-Alcázar, C Rangaswamy, R Panda, J Bitterling, YJ Simsek, ...
Science 358 (6367), 1202-1206, 2017
5082017
Placebo-controlled trial of oral laquinimod for multiple sclerosis
G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi
New England Journal of Medicine 366 (11), 1000-1009, 2012
4422012
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN …
JW Goldman, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ...
The Lancet Oncology 22 (1), 51-65, 2021
4222021
Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity
D Havrylyuk, B Zimenkovsky, O Vasylenko, L Zaprutko, A Gzella, R Lesyk
European journal of medicinal chemistry 44 (4), 1396-1404, 2009
3922009
Медичне право України: підручник
ІЯС Семен Григорович Стеценко, ВЮ Стеценко
К.: Всеукраїнська асоціація видавців «Правова єдність, 2008
379*2008
4-Thiazolidones: centenarian history, current status and perspectives for modern organic and medicinal chemistry
RB Lesyk, BS Zimenkovsky
Current Organic Chemistry 8 (16), 1547-1577, 2004
3672004
To NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps
S Boeltz, P Amini, HJ Anders, F Andrade, R Bilyy, S Chatfield, I Cichon, ...
Cell Death & Differentiation 26 (3), 395-408, 2019
3612019
Synthesis and anticancer activity evaluation of 4-thiazolidinones containing benzothiazole moiety
D Havrylyuk, L Mosula, B Zimenkovsky, O Vasylenko, A Gzella, R Lesyk
European Journal of Medicinal Chemistry 45 (11), 5012-5021, 2010
3382010
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet 381 (9884), 2167-2175, 2013
3352013
European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)
J Egea, I Fabregat, YM Frapart, P Ghezzi, A Görlach, T Kietzmann, ...
Redox biology 13, 94-162, 2017
3142017
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20